References
- Peters DJ and Breuning MH (2001) Autosomal dominant polycystic kidney disease: modification of disease progression. Lancet 358, 1439-1444 https://doi.org/10.1016/S0140-6736(01)06531-X
- Harris PC and Torres VE (2009) Polycystic kidney disease. Annu Rev Med 60, 321-337 https://doi.org/10.1146/annurev.med.60.101707.125712
- Ghata J and Cowley BD Jr (2017) Polycystic Kidney Disease. Compr Physiol 7, 945-975 https://doi.org/10.1002/cphy.c160018
- Sutters M and Germino GG (2003) Autosomal dominant polycystic kidney disease: molecular genetics and pathophysiology. J Lab Clin Med 141, 91-101 https://doi.org/10.1067/mlc.2003.13
- Watnick TJ, Piontek KB, Cordal TM et al (1997) An unusual pattern of mutation in the duplicated portion of PKD1 is revealed by use of a novel strategy for mutation detection. Hum Mol Genet 6, 1473-1481 https://doi.org/10.1093/hmg/6.9.1473
- Rossetti S, Hopp K, Sikkink RA et al (2012) Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol 23, 915-933 https://doi.org/10.1681/ASN.2011101032
- Pei Y (2001) A "two-hit" model of cystogenesis in autosomal dominant polycystic kidney disease? Trends Mol Med 7, 151-156 https://doi.org/10.1016/S1471-4914(01)01953-0
- Bodnar AG, Ouellette M, Frolkis M et al (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349-352 https://doi.org/10.1126/science.279.5349.349
- Counter CM, Hahn WC, Wei W et al (1998) Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A 95, 14723-14728 https://doi.org/10.1073/pnas.95.25.14723
- Lee KM, Choi KH and Ouellette MM (2004) Use of exogenous hTERT to immortalize primary human cells. Cytotechnology 45, 33-38 https://doi.org/10.1007/10.1007/s10616-004-5123-3
- Ouellette MM, McDaniel LD, Wright WE, Shay JW and Schultz RA (2000) The establishment of telomeraseimmortalized cell lines representing human chromosome instability syndromes. Hum Mol Genet 9, 403-411 https://doi.org/10.1093/hmg/9.3.403
- Hein J, Boichuk S, Wu J et al (2009) Simian virus 40 large T antigen disrupts genome integrity and activates a DNA damage response via Bub1 binding. J Virol 83, 117-127 https://doi.org/10.1128/JVI.01515-08
- Shirozu M, Nakano T, Inazawa J et al (1995) Structure and chromosomal localization of the human stromal cellderived factor 1 (SDF1) gene. Genomics 28, 495-500 https://doi.org/10.1006/geno.1995.1180
- Nagasawa T (2014) CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J Mol Med 92, 433-439 https://doi.org/10.1007/s00109-014-1123-8
- Sanchez-Martin L, Sanchez-Mateos P, Cabanas C (2013) CXCR7 impact on CXCL12 biology and disease. Trends Mol Med 19, 12-22 https://doi.org/10.1016/j.molmed.2012.10.004
- Liekens S, Schols D and Hatse S (2010) CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr Pharm Des 16, 3903-3920 https://doi.org/10.2174/138161210794455003
- Guyon A (2014) CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems. Front Cell Neurosci 8, 65 https://doi.org/10.3389/fncel.2014.00065
- Ghanem I, Riveiro ME, Paradis V, Faivre S, de Parga PM and Raymond E (2014) Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res 6, 340-352
- Scala S (2015) Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment. Clin Cancer Res 21, 4278-4285 https://doi.org/10.1158/1078-0432.CCR-14-0914
- Herbert BS, Grimes BR, Xu WM et al (2013) A telomerase immortalized human proximal tubule cell line with a truncation mutation (Q4004X) in polycystin-1. PLoS One 8, e55191 https://doi.org/10.1371/journal.pone.0055191
- Tan YC, Blumenfeld JD, Anghel R et al (2009) Novel method for genomic analysis of PKD1 and PKD2 mutations in autosomal dominant polycystic kidney disease. Hum Mutat 30, 264-273 https://doi.org/10.1002/humu.20842
- Jo HS, Eum WS, Park EY et al (2017) Effects of PEP-1-FK506BP on cyst formation in polycystic kidney disease. BMB Rep 50, 460-465 https://doi.org/10.5483/BMBRep.2017.50.9.090